What products does Galderma make that practices use?

Galderma's core injectables portfolio includes Restylane (hyaluronic acid filler), Dysport (abobotulinumtoxinA), and Sculptra (PLLA biostimulator). These are among the most widely used products in aesthetic practices for wrinkle reduction and facial volumization.

Does L'Oréal's ownership of Galderma mean it will be acquired?

L'Oréal's 20% stake functions as a strategic anchor that makes acquisition by a financial buyer unlikely in the near term. The investment signals L'Oréal's intent to maintain and grow Galderma as an operating company rather than sell it off.

How does L'Oréal's Galderma stake affect pricing and margins for practices?

Practice owners should monitor whether L'Oréal's ownership translates into pricing pressure or margin compression on Restylane and Dysport. L'Oréal's consumer-facing reach and potential retail partnerships could shift market dynamics around brand loyalty and rebate programs like Aspire and Evolus Rewards.

How does Galderma compete against other injectables companies?

Galderma competes directly against AbbVie/Allergan Aesthetics and Revance in the injectables market. L'Oréal's increased ownership underscores Galderma's competitive standing and suggests confidence in its ability to hold and grow market share.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Business & M&A

L'Oréal Boosts Galderma Stake to 20% — Strategic Consolidation in Aesthetics

L'Oréal's increased investment signals confidence in Galderma's injectables and skincare portfolio amid competitive pressure.

By Evan at Inside MedSpa · Jul 12, 2026

1-YEAR MOVE

LRLCY ▲0.3% ABBV ▲11.6% EOLS ▼15.6%

1-year price move by ticker
Ticker	Company	1-year change
LRLCY	L'Oréal (CeraVe · SkinCeuticals)	+0.3%
ABBV	AbbVie (Allergan Aesthetics)	+11.6%
EOLS	Evolus	−15.6%

L'Oréal has increased its stake in Galderma to 20%, deepening its strategic position in the medical-aesthetics and dermatology company. The move reflects L'Oréal's confidence in Galderma's portfolio—anchored by Restylane (HA filler), Dysport (abobotulinumtoxinA), and Sculptra (PLLA biostimulator)—and signals intent to leverage Galderma's distribution and clinical relationships across professional aesthetics and dermatology.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/loreal-raises-galderma-stake-to-20-percent/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

L'Oréal Boosts Galderma Stake to 20% — Strategic Consolidation in Aesthetics

Share

Discussion

Leave a comment

By the time it's news, it's too late.